Platelet-activating factor and human thyroid cancer

European Journal of Endocrinology

Volumn 153, Issue 1, 2005, Pages 31-40

  Denizot, Yves ^b   Chianéa, Thierry ^a   Labrousse, François ^a   Truffinet, Véronique ^b   Delage, Manuela ^a   Mathonnet, Muriel ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GOITER; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID ADENOMA; THYROID PAPILLARY CARCINOMA;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADENOMA; ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FIBROBLAST GROWTH FACTOR 2; GOITER; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; SEX FACTORS; THYROID GLAND; THYROID NEOPLASMS; THYROIDITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 22744459601     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01947     Document Type: Article

References (32)

1. Segev DL, Umbricht C & Zeiger MA. Molecular pathogenesis of thyroid cancer. Surgical Oncology 2003 12 69-90.
2. Huang MC, Graeler M, Shankar G, Spencer J & Goetzl EJ. Lysophospholipid mediators of immunity and neoplasia. Biochimica et Biophysica Acta 2002 1582 161-167.
3. Murakami-Murofushi K, Uchiyama A, Fujiwara Y, Kobayashi T, Kobayashi S, Mukai M, Murofushi H & Tigyi G. Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochimica et Biophysica Acta 2002 1582 1-7.
4. Ogretmen B & Hannon YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews. Cancer 2004 4 604-616.
5. 31P high-resolution NMR study. NMR in Biomedicine 2000 13 8-13.
6. 1H-NMR of dolichol, cholesterol and choline-containing lipids in extracts of normal and pathological thyroid tissue. NMR in Biomedicine 2000 13 377-383.
7. Schulte KM, Beyer A, Köhrer K, Oberhäuser S & Röher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: overexpression of the high-affinity receptor EDG4 in differentiated thyroid cancer. International Journal of Cancer 2001 92 249-256.
8. Denizot Y, Guglielmi L, Donnard M & Trimoreau F. Platelet-activating factor and normal or leukaemic haematopoiesis. Leukemia and Lymphoma 2003 44 775-782.
9. Arai H, Koizumi H & Inoue K. Platelet-activating factor acetylhydrolase (PAF-AH). Journal of Biochemistry 2002 131 634-640.
10. Izumi T & Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochimica et Biophysica Acta 1995 1259 317-333.
11. Youlyouz I, Magnoux E, Guglielmi L & Denizot Y. Expression of a splice variant of the platelet-activating factor receptor transcript 2 in various human cancer cell lines. Mediators of Inflammation 2002 11 329-331.
12. Maggi M, Bonaccorsi L, Finetti G, Carloni V, Muratori M, Laffi G, Forti G, Serio M & Baldi E. Platelet-activating factor mediates an autocrine proliferative loop in endometrial adenocarcinoma cell line HEC-1A. Cancer Research 1994 54 4777-4784.
13. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G & Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. American Journal of Pathology 2000 157 1713-1715.
14. Mannori G, Barletta E, Mugnai G & Ruggieri S. Interaction of tumor cells with vascular endothelia: role of platelet-activating factor. Clinical and Experimental Metastasis 2000 18 89-96.
15. Tripathi YB, Kandala JC, Guntaka RV, Lim RW & Shukla SD. Platelet-activating factor induces expression of early response genes c-fos and TIS-1 in human epidermoid carcinoma A-431 cells. Life Sciences 1991 49 1761-1767.
16. Montrucchio G, Lupia E, Battaglia E, Del Sorbo L, Boccellino M, Biancone L, Emanuelli G & Camussi G. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 80-88.
17. Montrucchio G, Sapino A, Bussolati B, Ghisolfi G, Rizea-Savu S, Silvestro L, Lupia E & Camussi G. Potential angiogenic role of platelet-activating factor in human breast cancer. American Journal of Pathology 1998 153 1589-1596.
18. Sirois MG & Edelman ER. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. American Journal of Physiology 1997 272 H2746-H2756.
19. Deo DD, Axelrad TW, Robert EG, Marcheselli V, Bazan NG & Hunt JD. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelia cells. Journal of Biological Chemistry 2002 277 21237-21245.
20. Ramsden JD. Angiogenesis in the thyroid gland. Journal of Endocrinology 2000 166 475-480.
21. Denizot Y, Desplat V, Drouet M, Bertin F & Melloni B. Is there a role of platelet-activating factor in human lung cancer? Lung Cancer 2001 33 195-202.
22. Pitton C, Lanson M, Besson P, Fetissoff F, Lansac J & Benveniste J. Presence of PAF-acether in human breast carcinoma: relation to axillary lymph node metastasis. Journal of the National Cancer Institute 1989 81 1298-1302.
23. Denizot Y, Gainant A, Guglielmi L, Bouvier S, Cubertafond P & Mathonnet M. Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients. Oncogene 2003 22 7222-7224.
24. Denizot Y, Descottes B, Truffinet V, Valleix D, Labrousse F & Mathonnet M. Platelet-activating factor and liver metastasis of colorectal cancer. International Journal of Cancer 2005 113 503-505.
25. Döbert N, Menzel C, Oeschger S & Grünwald F. Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid 2004 14 65-70.
26. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F & Barone C. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. British Journal of Cancer 1998 78 765-770.
27. Denizot Y, Truffinet V, Bouvier S, Gainant A, Cubertafond P & Mathonnet M. Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer. Mediators of Inflammation 2004 13 53-54.
28. Denizot Y, Liozon E, Guglielmi L, Ly K, Soria P, Loustaud V, Vidal E & Jauberteau MO. No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis. Mediators of Inflammation 2003 12 101-105.
29. Botitsi E, Mavri-Vavayanni M & Siafaka-Kapadai A. Metabolic fate of platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and lyso-PAF (1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine) in FRTL5 cells. Journal of Lipid Research 1998 39 1295-1304.
30. Larsson Forsell PKA, Kennedy BP & Claesson HE. The human calcium-independent phospholipase A2 gene. Multiple enzymes with distinct properties from a single gene. European Journal of Biochemistry 1999 262 575-585.
31. Haye B, Aublin JL, Champion S, Lambert B & Jacquemin C. Interactions between thyreostimulin and PAF-acether on thyroid cell metabolism. European Journal of Pharmacology 1984 104 125-131.
32. Abramovici Y, Boucekkine N, Remy JJ, Salamero J & Charreire J. Control of the proliferation and differentiation of GEJ under platelet-aggregating factor treatment. Acta Endocrinologica. Supplementum 1987 281 264-266.